未登录 分享 收藏
分享 收藏
分享 收藏
分享 收藏
分享 收藏
分享 收藏
分享 收藏
分享 收藏
Phase I trial of the DLL3/CD3 IgG-like T cell engager BI 764532 in patients (pts) with DLL3+tumors: Focus on Asian pts Kuboki, Y.; Gambardella, V.; Capdevila Castillon, J.; Alese, O. B.; Morgensztern, D.; Sayehli, C. M.; Sanmamed, M. F.; Arriola, E.; Wolf, J.; Owonikoko, T. K.; Studeny, M.; Bouzaggou, M.; Song, E.; Wermke, M. 分享 收藏
Tarlatamab for patients (pts) with previously treated small cell lung cancer (SCLC): Primary analysis of the phase II DeLLphi-301 study Paz-Ares, L.; Ahn, M-J.; Felip, E.; Handzhiev, S.; Korantzis, I.; Izumi, H.; Ohashi, K.; Majem Tarruella, M.; Wolf, J.; Reck, M.; Hummel, H-D.; Blackhall, F.; Dingemans, A-M. C.; Owonikoko, T. K.; Ramalingam, S. S.; Sands, J.; Jiang, T.; Mukherjee, S.; Anderson, E.; Cho, B. C. 分享 收藏
The nNGM Preclinical Platform: Preclinical research to generate evidence for patients with non-small cell lung cancer harboring variants of unknown significance Ziegler, M.; Albers-Leischner, C.; Salgueiro, L.; Khoury, N.; Sharapova, Y.; Saalfeld, F. C.; Wenzel, C.; Scharpenseel, H.; Schmidt, C.; Naveja-Romero, J.; Meemboor, S.; Hillmer, A.; Nogova, L.; Wermke, M.; Wolf, J.; Diederichs, S.; Brummer, T.; Buettner, R.; Janning, M.; Loges, S. 分享 收藏
FIND: A phase II study to evaluate the efficacy of erdafitinib in FGFR-altered NSCLC Nogova, L.; Malchers, F.; Hillmer, A.; Terjung, I.; Scharpenseel, H.; Merkelbach-Bruse, S.; Scheel, A.; Siemanowski, J.; Scheffler, M.; Frank, J.; Heiden, P.; Hummel, H-D.; Wermke, M.; Grohe, C.; Kron, A.; Reinmuth, N.; Griesinger, F.; Thomas, R.; Buettner, R.; Wolf, J. 分享 收藏
Capmatinib vs docetaxel as second- or third-line (2/3L) therapy in patients (pts) with METex14-mutated advanced NSCLC (aNSCLC): The GeoMETry-III trial Vidal, O. J. Juan; Singhal, M. K.; Alvarez, R. M.; Cecere, F. L.; Souquet, P-J.; Kim, S-W.; Robeva, A.; Jary, A.; Glaser, S.; Miskic, M.; Wolf, J. 分享 收藏
分享 收藏
Characterization of the essential role of bone morphogenetic protein 9 (BMP9) in osteogenic differentiation of mesenchymal stem cells (MSCs) through RNA interference (vol 5, pg 172, 2018) Yan, Shujuan; Zhang, Ruyi; Wu, Ke; Cui, Jing; Huang, Shifeng; Ji, Xiaojuan; An, Liping; Yuan, Chengfu; Gong, Cheng; Zhang, Linghuan; Liu, Wei; Feng, Yixiao; Zhang, Bo; Dai, Zhengyu; Shen, Yi; Wang, Xi; Luo, Wenping; Liu, Bo; Haydon, Rex C.; Lee, Michael J.; Reid, Russell R.; Wolf, Jennifer Moriatis; Shi, Qiong; Luu, Hue H.; He, Tong-Chuan; Weng, Yaguang 分享 收藏
Sox9 augments BMP2-induced chondrogenic differentiation by downregulating Smad7 in mesenchymal stem cells (MSCs) (vol 4, pg 229, 2017) Zhao, Chen; Jiang, Wei; Zhou, Nian; Liao, Junyi; Yang, Mingming; Hu, Ning; Liang, Xi; Xu, Wei; Chen, Hong; Liu, Wei; Shi, Lewis L.; Oliveira, Leonardo; Wolf, Jennifer Moriatis; Ho, Sherwin; Athiviraham, Aravind; Tsai, H. M.; He, Tong-Chuan; Huang, Wei 分享 收藏
Response to capmatinib in patients (pts) with advanced non-small cell lung cancer (NSCLC) and MET exon 14 skipping (METex14) mutation: Whole transcriptome analysis from phase II GEOMETRY Mono-1 study 晚期非小细胞肺癌 (NSCLC) 和MET外显子14跳跃 (METex14) 突变患者 (pts) 对卡马替尼的反应: 来自II期几何Mono-1研究的全转录组分析 Wolf, J.; Groen, H. J. M.; Tan, D. S. W.; Garon, E. B.; Demanse, D.; Robeva, A.; Yovine, A.; Fairchild, L.; Boran, A. D.; Heist, R. 分享 收藏
Efficacy and safety of capmatinib plus spartalizumab in treatment-naive patients with advanced NSCLC harboring MET exon 14 skipping mutation Wolf, J.; Heist, R.; Kim, T. M.; Nishio, M.; Dooms, C.; Kanthala, R. R.; Leo, E.; Giorgetti, E.; Wang, Y.; Mardjuadi, F. I.; Cortot, A. 分享 收藏
BIOLUMA: A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in lung cancer and to evaluate biomarkers predictive for response - results from the NSCLC cohort Fischer, R. N.; George, J.; Scheel, A.; Schloesser, H.; Brossart, P.; Engel-Riedel, W.; Griesinger, F.; Grohe, C.; Kern, J. K.; Panse, J.; Sebastian, M.; Serke, M.; Wiewrodt, R.; Michels, S.; Nogova, L.; Riedel, R.; Weber, J-P.; Buettner, R.; Thomas, R.; Wolf, J. 分享 收藏
EGFR exon 20 insertions in non-small cell lung cancer (NSCLC): Impact of TP53 mutation status and value of immune checkpoint blockade (ICB) Kron, A.; Scheffler, M.; Ihle, M.; Michels, S.; Sueptitz, J.; Prang, D.; Jakobs, F.; Nogova, L.; Fischer, R. N.; Eisert, A. K.; Riedel, R.; Kron, F.; Hillmer, A.; Loges, S.; Merkelbach-Bruse, S.; Buettner, R.; Wolf, J. 分享 收藏
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
分享.png){kind=icon}
收藏.png)
ANNALS OF ONCOLOGY.png)
OAAI